GlassScriptPhysician profile
Nicholas S Dressel
NPI 1285110494
$6,072.35
in general payments reported to CMS, 2019-2025
39 companies · $873 in 2025
The $873 reported for 2025 was more than what 84% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $800 · 2022: $998 · 2023: $1,727 · 2024: $1,675 · 2025: $873.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,274.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,274.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $781.65 | 2021-2025 | Otezla, Repatha, Evenity |
| Glaxosmithkline, LLC. | $759.34 | 2021-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Abbvie INC. | $612.38 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $570.02 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Lilly USA, LLC | $552.13 | 2021-2025 | Zepbound, Mounjaro, Jardiance |
| Novo Nordisk INC | $482.27 | 2022-2025 | Ozempic, Wegovy, Rybelsus |
| Janssen Pharmaceuticals, INC | $312.32 | 2021-2025 | Spravato |
| Pfizer INC. | $311.89 | 2021-2025 | |
| Astellas Pharma US INC | $261.04 | 2023-2024 | Veozah |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $167.75 | 2022-2024 | Xifaxan |
| Idorsia Pharmaceuticals US INC | $159.52 | 2022-2024 | Quviviq |
| E.R. Squibb & Sons, L.L.C. | $132.61 | 2021-2023 | Eliquis, Camzyos |
| Merck Sharp & Dohme LLC | $94.90 | 2021-2025 | Belsomra, Capvaxive, Gardasil 9 |
| Amarin Pharma, INC. | $81.83 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $72.21 | 2021-2022 |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicholas Dressel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.